drugset / Trial / NCT04391569
Randomized Therapy In Status Epilepticus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluated the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
Timeline
- Start
- 2020-12-09
- Primary completion
- 2024-03-30
- Completion
- 2024-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ganaxolone | Small molecule | — | Intravenous |
Indications
No indication recorded.